scispace - formally typeset
Search or ask a question

Showing papers by "Hande Turna published in 2017"

Journal Article•DOI•
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

[...]

Achim Rittmeyer, Fabrice Barlesi1, Daniel Waterkamp2, Keunchil Park3, Fortunato Ciardiello4, Joachim von Pawel, Shirish M. Gadgeel5, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo Dols, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios6, Fairooz F. Kabbinavar7, Osvaldo Arén Frontera, Filippo de Marinis8, Hande Turna9, Jong Seok Lee10, Marcus Ballinger2, Marcin Kowanetz2, Pei He2, Daniel S. Chen2, Alan Sandler2, David R. Gandara11 •
Aix-Marseille University1, Genentech2, Samsung Medical Center3, Seconda Università degli Studi di Napoli4, Wayne State University5, Pontifícia Universidade Católica do Rio Grande do Sul6, University of California, Los Angeles7, European Institute of Oncology8, Istanbul University9, Seoul National University Bundang Hospital10, University of California, Davis11
21 Jan 2017-The Lancet
TL;DR: Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations, and overall survival improvement was similar in patients with squamous non-squamous lung cancer.

3,496 citations

Journal Article•DOI•
Outcomes of Turkish National Breast Cancer Registry.

[...]

Saadettin Kilickap1, Mahmut Gumus2, Dogan Uncu, Metin Ozkan, Irfan Cicin3, Tamer Elkiran4, Abdurrahman Isikdogan5, Aziz Karaoglu6, Berna Oksuzoglu, Feyyaz Ozdemir, Hande Turna7, Ruchan Uslu8, Ozgur Ozyilkan9, Alper Erdogan10, Burce Goktas10, Oguz Kara11 •
Hacettepe University1, Istanbul Medeniyet University2, Trakya University3, İnönü University4, Dicle University5, Dokuz Eylül University6, Istanbul University7, Ege University8, Başkent University9, Hoffmann-La Roche10, Çukurova University11
30 May 2017-Journal of Clinical Oncology
TL;DR: This multicenter, cross-sectional, non-interventional study conducted on new and previously diagnosed BC cases applied to 28 medical oncology outpatient clinics between 2012 and 2015 collected demographic, diagnostic, treatment, and outcome information about Turkish patients with breast cancer.
Abstract: Background: The aim of this registry was to collect demographic, diagnostic, treatment, and outcome information about Turkish patients with breast cancer (BC). Methods: It was designed as a multicenter, cross-sectional, non-interventional study conducted on new and previously diagnosed BC cases applied to 28 medical oncology outpatient clinics between 2012 and 2015. A total of 16841 male (n = 153) and female (n = 16688) patients > 18 years were included. Results: Mean age of BC patients was 52.0±11.5 years. Among women, 53.7% were postmenopausal, and 24.4% were receiving hormone replacement (HRT) and/or oral contraceptive therapies (OCT). At time of diagnosis, 18.2% of patients presented with Stage 1, 48.5% with Stage 2, 25.5% with Stage 3, and 7.9% with Stage 4 BC. In 79,8% of the patients histopathology was invasive ductal carcinoma. Estrogen (ER) and progesterone receptors (PR) were positive in 74.7%, and 69.4% of patients, respectively. Diagnostic immunohistochemistry (IHC) was performed in 90.4% of p...

3 citations